JPX · 4570.T
Immuno-Biological Laboratories Co., Ltd.
¥1,027-¥12 (-1.15%)
Immuno-Biological Laboratories Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 73.12% below the high.
Loading market information…
JPX · 4576.T · JPY
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
D. Western Therapeutics Institute, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.85% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
D. Western Therapeutics Institute, Inc.’s next earnings report is currently expected on Nov 12, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow D. Western Therapeutics Institute, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutions prescribed for glaucoma and ocular hypertension, as well as DW-1001, another medication for eye conditions. It also provides DWR-2206, a regenerative cell-based product targeting bullous keratopathy, and DW-1002, an ophthalmic surgical aid used for staining membranes like ILM, ALC, ERM, and PVR during cataract operations. In its development pipeline, the company is advancing DW-5LBT, a lidocaine patch designed to alleviate neuropathic pain post-shingles. Additionally, K-321 is progressing through Phase III clinical trials for Fuch endothelial corneal dystrophy, and H-1337, a multi-kinase inhibitor, has commenced Phase IIb trials for glaucoma and ocular hypertension treatment. The firm was established in 1999 and operates from its headquarters in Nagoya, Japan.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:17 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
¥1,027-¥12 (-1.15%)
Immuno-Biological Laboratories Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 73.12% below the high.
¥57-¥1 (-1.72%)
Kubota Pharmaceutical Holdings Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 83.71% below the high.
¥363-¥6 (-1.63%)
Carna Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.1% below the high.
¥559-¥5 (-0.89%)
Cyfuse Biomedical K.K.’s quoted price sits in the lower half of its reported 52-week range, 26.83% below the high.
¥212-¥2 (-0.93%)
Soiken Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.77% below the high.
¥132+¥2 (+1.54%)
PRISM BioLab Co.,LTD’s quoted price sits in the lower half of its reported 52-week range, 52.69% below the high.
¥64-¥2 (-3.03%)
Ribomic Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.67% below the high.
¥215+¥1 (+0.47%)
Trans Genic Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.85% below the high.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
